Your SlideShare is downloading. ×
Desembre activitat 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Desembre activitat 2013

98
views

Published on

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
98
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Desembre 2013 Actualització farmacoterapèutica en Esclerosi Múltiple @APR_300
  • 2. Presentació Objectiu: recollir les novetats sobre farmacoteràpia de l’Esclerosi Múltiple publicats en les diferents revistes biomèdiques. En aquest document, hi podràs trobar reunits els tuits de cada mes del compte de Twitter @APR_300 per a una lectura més fàcil. La present informació està dirigida a professionals sanitaris. En cas que siguis un pacient, comenta qualsevol dubte amb un professional sanitari. Tipus d’informació: orientat a la farmacoteràpia i aspectes relacionats com la farmacogenètica o la farmacoeconomia i també alguns estudis de recerca bàsica. Filtre d’idioma: articles publicats en anglès, català o castellà. No hi ha conflictes d’interessos. No es pretén afavorir a cap fàrmac. El volum d’informació de cada apartat dependrà exclusivament del nombre d’articles publicats/ localitzats. Autora: Ariadna Pérez Ricart Farmacèutica hospitalària Twitter: @APR_300 Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 3. Aquest mes, notícies sobre: -Interferons -Acetat de glatiràmer -Fingolimod -Natalizumab -Laquinimod -Daclizumab -Alemtuzumab -Rituximab -Vitamina D -Espasticitat -Vacuna Bacille Calmette-Guérin -4-aminopiridina -Dalfampridine Fampridine / -Genètica -Pediatria -Embaràs Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 4. DESEMBRE 2013 Esdeveniments destacats: 15 de desembre: La Marató de TV3. Malalties neurodegeneratives. 18 de desembre: Dia Nacional de l’Esclerosi Múltiple Tuits: Interferons - Intramuscular IFNß-1a in multiple sclerosis: ‘no proof of effectiveness’ or ‘proof of no effectiveness’? http://bit.ly/18wkXdD Eur J Neurol - Assessing treatment response to interferon-β http://bit.ly/1cEgRPn Neurology - ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study http://1.usa.gov/19BRVnm Med Devices - Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report. http://bit.ly/19ymfTF J Med Cas Rep -Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes http://bit.ly/1jNpvyr J Neur Neurosurg Psychiatry -Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. http://bit.ly/19fKyb2 J Neur Neurosurg Psychiatry Acetat de glatiràmer -Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. http://bit.ly/1cjLwkZ CNS Drugs Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 5. Fingolimod -Five-year results from a phase 2 study of oral fingolimod in relapsing remiting multiple sclerosis http://bit.ly/18Sp2GV Mult Scler - Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis bit.ly/1eDV8Xr Curr Med Res Opin - Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study http://bit.ly/1eQkB0C J Neurol - Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis via CIMSFHUVH http://bit.ly/1czgHc8 Eur J Clin Pharmacol Natalizumab - Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial multiple sclerosis http://bit.ly/1bc3xx1 Eur J Neurol -Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango http://bit.ly/1iwlFeO Expert Opin Biol Ther -A benefit-risk analysis of natalizumab in the treatment of pa tients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy http://bit.ly/1bGGj8w Curr Med Res Opin -Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients http://bit.ly/J2RmMh Mult Scler - Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning http://bit.ly/1aLolLV Mult Scler - Smokers run increased risk of developing anti-natalizumab antibodies http://bit.ly/IPnN0G Mult Scler - Risk acceptance in multiple sclerosis patients on natalizumab treatment. http://bit.ly/1c1hliE Plos One - Consenso español actualizado sobre el uso del natalizumab via CIMSFHUVH i BibliotecaHUVH http://bit.ly/1c3hrpT Neurologia Laquinimod -Multiple sclerosis: Oral laquinimod for MS—bringing the brain into focus http://bit.ly/1gJIvLU Nature Reviews Neurology Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 6. Daclizumab -Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis http://bit.ly/1d3qrtn Expert Rev Clin Pharmacol - Assessing dalfampridine efficacy in the physician’s office http://bit.ly/1bN5Kz6 Mult Scler - Effect of daclizumab high-yield process in patients with highly active relapsingremitting multiple sclerosis http://bit.ly/19UK7RA J Neurol Alemtuzumab -Current evaluation of alemtuzumab in multiple sclerosis. http://bit.ly/1g3vjUk Expert Opin Biol Ther Rituximab -Rituximab for relapsing-remitting multiple sclerosis. http://bit.ly/199urtv Cochrane Database Syst Rev Vitamina D -1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization. http://1.usa.gov/1bWqV7Z Proc Nat Acad SCI USA Tractaments simptomàtics -Bladder management in MS http://bit.ly/1bDvp1A Phys Med Rehabil Clin N Am -Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) http://bit.ly/1dYNxq3 Eur J Health Econ - Vision and multiple sclerosis http://bit.ly/IzkLya Multiple Sclerosis & related disorders -Pharmacological treatment for memory disorder in multiple sclerosis Cochrane Database Syst Rev http://bit.ly/1cl0REV -4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review http://bit.ly/1e3AQ91 Ther Adv Neurol Disord - Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS http://bit.ly/KeX8LM Neurology Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 7. Tractaments simptomàtics -Espasticitat -Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study http://bit.ly/1b8DY3j Int J Neurosci -MultipleSclerosis spasticity epidemiology – key publications. http://bit.ly/1hryKEX Exp Rev Neurother -MultipleSclerosis spasticity management – key publications http://bit.ly/1j8StbM Exp Rev Neurother -Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice http//bit.ly/IDkRVK Exp Rev Neurother -Advances in the management of MultipleSclerosis spasticity: guidelines http://bit.ly/1b6YrXk Exp Rev Neurother -Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe http://bit.ly/1cgatOm Exp Rev Neurother -Dalfampridine / Fampridine -Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis http://bit.ly/18vTo47 Curr Med Res Opin -Long-term effects of dalfampridine in patients with multiple sclerosis. http://bit.ly/19fcwxO J Neurol Sci - Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis http://bit.ly/1bp3CNO Multiple Sclerosis & related disorders Transplantament hematopoiètic i noves teràpies - Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage in Multiple Sclerosis. Hope for Novel Therapies? http://bit.ly/1d6r0T3 JAMA Neurol -Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: A pilot, open-label study with neurophysiological measurements http://bit.ly/1c2T2fK Neurophysiol Clin -Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis http://bit.ly/J2QQxV Mult Scler - Effects of Bacille Calmette-Guérin vaccine after the first demyelinating event in the CNS multiple sclerosis http://bit.ly/1bhXln6 Neurology Genètica -Decoding multiple sclerosis: an update on genomics and future directions http://bit.ly/19chLOE Expert Rev Neurother -Body fluid biomarkers in multiple sclerosis http:// bit.ly/1gjp8f1 Lancet Neurol Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 8. Pediatria i Embaràs - Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders http://bit.ly/1cubeDo J Neurol Neurosurg Psychiatry -Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for multiple sclerosis http://bit.ly/19aPSfS CNS Drugs Altres -Esclerosis múltiple en el contexto español http://bit.ly/1eIIVkd Rev Neurol -Risk evaluation and monitoring in multiple sclerosis therapeutics http://bit.ly/18SpCEL Mult Scler -Multiple sclerosis and related disorders: groundbreaking news http://bit.ly/1d4LawM Lancet Neurol - Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients http://bit.ly/1bvI4PT Int J Clin Pharm - A network meta-analysis of randomized controlled trials comparing the effectiveness and safety profile of treatments for relapsing multiple sclerosis via CIMSFHUVH http://bit.ly/1bMESQ3 J Clin Pharm Ther -New and emerging immune-targeted drugs for the treatment of multiple sclerosis. http://bit.ly/18BAfxn Br J Clin Pharmacol -Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. http://bit.ly/1dwuWg7 Biologics - Novel Immunomodulatory Approaches for the Management of multiple sclerosis via @velezmeca http://bit.ly/1l0MJyJ Clin Pharmacol Ther - Antimyelin antibodies as predictors of disability after clinically isolated syndrome http://bit.ly/1e65OgI Int J Neurosci -Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis http://bit.ly/19aFO46 J Neurosci Nurs Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 9. Pacients -Esclerosis multiple en linea: Incontinencia urinaria. Vídeos per a pacients de @FundacioGaem -RT@neurodidacta: embarazo, lactancia o anticoncepción en esclerosis múltiple de la Dra Mar Mendibe http://bit.ly/IowXS8 vía @redpacientes -RT@VHIR_:El Dr. @XMontalban encercla l'esclerosi múltiple a Càpsules de Ciència Televisió de Catalunya: http://bit.ly/1cSOk6Z via @tv3cat -Lazo Múltiple: app per la difusió i la conscienciació sobre l'Esclerosis Múltiple http://bit.ly/1g7zKhd Agències de medicaments i altres notícies -Review of Dimethyl fumarate http://bit.ly/1eMhnKF AustPrescriber - Estudio de la retina para visualizar la evolución de la esclerosis múltiple via seneurologia http://bit.ly/1aPrD0L - La vitamina D podria aliviar los síntomas de la EM via fundcerebro http://bit.ly/18Ujnm2 Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.